- Home
- FMST vs INDP Comparison
FMST vs INDP Comparison
Compare FMST & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- INDP
- Stock Information
- Founded
- FMST 2005
- INDP 2000
- Country
- FMST Canada
- INDP United States
- Employees
- FMST N/A
- INDP N/A
- Industry
- FMST Other Metals and Minerals
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- INDP Health Care
- Exchange
- FMST Nasdaq
- INDP Nasdaq
- Market Cap
- FMST 15.9M
- INDP 15.4M
- IPO Year
- FMST N/A
- INDP N/A
- Fundamental
- Price
- FMST $2.83
- INDP $1.16
- Analyst Decision
- FMST
- INDP Strong Buy
- Analyst Count
- FMST 0
- INDP 1
- Target Price
- FMST N/A
- INDP $12.00
- AVG Volume (30 Days)
- FMST 6.4K
- INDP 22.5K
- Earning Date
- FMST 01-01-0001
- INDP 11-04-2024
- Dividend Yield
- FMST N/A
- INDP N/A
- EPS Growth
- FMST N/A
- INDP N/A
- EPS
- FMST N/A
- INDP N/A
- Revenue
- FMST N/A
- INDP N/A
- Revenue This Year
- FMST N/A
- INDP N/A
- Revenue Next Year
- FMST N/A
- INDP N/A
- P/E Ratio
- FMST N/A
- INDP N/A
- Revenue Growth
- FMST N/A
- INDP N/A
- 52 Week Low
- FMST $1.77
- INDP $1.03
- 52 Week High
- FMST $4.25
- INDP $3.25
- Technical
- Relative Strength Index (RSI)
- FMST 42.92
- INDP 36.05
- Support Level
- FMST $2.65
- INDP $1.11
- Resistance Level
- FMST $2.95
- INDP $1.27
- Average True Range (ATR)
- FMST 0.21
- INDP 0.13
- MACD
- FMST -0.04
- INDP -0.00
- Stochastic Oscillator
- FMST 28.12
- INDP 22.03
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Lithium Resource & Technology Ltd is a hard-rock exploration company strategically located to capitalize on the growing EV appetite and is committed to being a supplier of North America's lithium feedstock. As the transition towards decarbonization, the company is focused on the exploration and growth of its five Lithium Lane Projects in Snow Lake Manitoba. It also has the Winston Gold/Silver Property in New Mexico, USA. The company mainly operates in one reportable operating segment being the acquisition and exploration of exploration and evaluation assets.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.